CT-388: Side Effects

Safety Overview#

CT-388's safety profile has been characterized in Phase 1b and Phase 2 trials. The Phase 1 MAD study reported that 83.3% of CT-388 participants experienced one or more GI-related treatment-emergent adverse events, with all TEAEs being mild to moderate in severity. In Phase 2, the discontinuation rate due to adverse events was low at 5.9% for CT-388 versus 1.3% for placebo.

Gastrointestinal Adverse Events#

GI events were the most common adverse events in CT-388 clinical trials:

Phase 1b Safety#

• 83.3% of participants experienced one or more GI-related TEAEs
• All TEAEs were mild to moderate in severity
• No serious adverse events
• No discontinuations due to adverse events
• No deaths

Phase 2 Safety#

• GI adverse events were mostly mild to moderate
• Consistent with the incretin class of medicines
• Discontinuation due to AEs: 5.9% (CT-388) vs 1.3% (placebo)

Most Common TEAEs#

• Decreased appetite: Most common overall (pharmacological effect)
• Nausea: Common during dose escalation
• Vomiting: Transient, generally mild to moderate
• Diarrhea: Common, self-limiting

Biased Signaling and Tolerability#

CT-388's signal-biased mechanism (minimal beta-arrestin recruitment) may contribute to favorable tolerability compared to balanced agonists. By reducing receptor desensitization, the biased signaling could allow lower effective doses or more gradual dose escalation while maintaining efficacy. However, this theoretical advantage requires further validation in head-to-head studies.

Treatment Discontinuation#

Discontinuation rates due to adverse events were notably low:

• Phase 1b: No discontinuations due to adverse events
• Phase 2: 5.9% (CT-388) vs 1.3% (placebo)

These rates compare favorably to other GLP-1/GIP agonists and suggest good overall tolerability.

GLP-1 Agonist Class Warnings#

As a dual GLP-1/GIP receptor agonist, CT-388 is expected to carry standard GLP-1 class warnings:

Thyroid C-Cell Tumors#

GLP-1 receptor agonists carry a class-wide warning for thyroid C-cell tumors observed in rodent studies. CT-388 would be expected to carry similar warnings and contraindications for MTC/MEN2.

Pancreatitis#

GLP-1 agonists have been associated with pancreatitis. Patients should report persistent severe abdominal pain.

Gallbladder Disease#

The substantial weight loss produced by CT-388 (22.5% at 48 weeks) increases the risk of cholelithiasis and cholecystitis.

Acute Kidney Injury#

GI adverse events may cause dehydration, which could contribute to acute kidney injury.

Heart Rate Effects#

GLP-1 agonists typically increase resting heart rate by 2-4 bpm. Heart rate effects specific to CT-388 have not been separately characterized in published data.

Special Populations#

Full data on CT-388 safety in renal impairment, hepatic impairment, elderly, and pediatric populations are not yet available.

Drug Interactions#

• Insulin and sulfonylureas: Dose reduction may be needed due to hypoglycemia risk
• Oral medications: GLP-1 receptor agonism delays gastric emptying, potentially affecting absorption
• Oral contraceptives: Consider alternative contraception during initiation

Safety Profile Context#

CT-388 belongs to the Metabolic category of research peptides. Understanding the side effect profile of CT-388 is essential for researchers designing clinical protocols and for healthcare providers advising patients. The side effects documented here are based on available clinical trial data and may not represent the complete safety profile.

Reported Side Effects#

The following side effects have been documented in clinical studies of CT-388. Side effect severity and frequency are based on available clinical data.

Decreased appetite#

Severity: mild | Frequency: very-common

Most common adverse event overall. Reported in 100% of CT-388 treated participants in the Phase 1 MAD study (vs 0% placebo). Expected pharmacological effect of dual GLP-1/GIP agonism.

Nausea#

Severity: mild | Frequency: very-common

Very common GI adverse event. Generally mild to moderate, most common during dose escalation, tends to improve with continued treatment.

Vomiting#

Severity: mild | Frequency: common

Common GI adverse event during dose escalation. Generally transient and mild to moderate in severity.

Diarrhea#

Severity: mild | Frequency: common

Commonly reported GI adverse event. Usually mild to moderate and self-limiting.

Injection site reactions#

Severity: mild | Frequency: common

Reported with subcutaneous injection. Generally mild and consistent with other injectable peptide therapies.

Contraindications#

The following contraindications have been identified for CT-388 based on available research and pharmacological considerations:

• CT-388 is investigational and not approved for any indication. Use only within clinical trials.
• Expected GLP-1 agonist class contraindication: personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Pregnancy (GLP-1 agonist class)
• Prior serious hypersensitivity to CT-388 or excipients

Individuals with any of these conditions should not use CT-388 without consulting a qualified healthcare provider.

Drug Interactions#

The following potential drug interactions have been identified for CT-388:

• Insulin and sulfonylureas: Increased risk of hypoglycemia when combined (GLP-1 agonist class interaction)
• Oral medications: GLP-1 receptor agonists may delay gastric emptying and affect absorption of co-administered oral drugs
• Oral contraceptives: Gastric emptying delay may reduce absorption; consider non-oral contraception during initiation

Drug interaction studies for CT-388 remain limited. Researchers should exercise caution when combining CT-388 with other compounds and consult relevant pharmacological references.

Related Reading#

• CT-388 overview and research guide
• CT-388 dosing protocols
• CT-388 risks and legal status